Johnson Winter & Slattery advised Blackmores on its agreement to acquire 100% of the shares in Catalent Australia Holding Pty Ltd, which owns and operates a tablet and softgel manufacturing facility in Braeside, Victoria.
There is an 18 month pre-completion period to allow Catalent to migrate third-party customers to its other facilities and Blackmores to move more of its products into the Braeside facility, with completion scheduled to occur before 31 October 2019.
The acquisition is intended to give Blackmores increased control and agility to respond to changing market conditions while also helping Blackmores ‘future proof’ its Asian business.
Corporate partner Jeremy Davis led the JWS team with assistance from the corporate, tax, employment and IP teams.
K&L Gates advised Catalent Pharma Solutions, Limited (a subsidiary of Catalent, Inc, which is headquartered in New Jersey and listed on the New York Stock Exchange).
JWS is engaged by major Australian and international corporations and investment funds as legal counsel on their most challenging transactions and disputes throughout Australia and surrounding regions.
Our representation of major corporations in many landmark and transformational deals and complex disputes positions us as a leading independent Australian firm.
With an appreciation of our client's commercial needs, we blend legal expertise with commercial and market awareness to deliver high quality legal services. This means working closely with clients and their in-house counsel to understand their commercial objectives, and ensuring our approach is tailored to deliver timely commercial outcomes.
Our higher ratio of senior lawyers means clients engage directly with the tactical minds and industry expertise required to succeed in complex and high stakes deals and disputes. A partnership ethos of service, technical excellence and collaboration ensures the most relevant specialist expertise and experience is brought to bear on every assignment.
Jessica Mitchell, Business Development Executive
T. +61 2 8247 9627
Be the first to receive the latest articles, news and publications.